Kantipur Pharmaceuticals Lab Limited Issuing IPO Shares to Locals of Kavrepalanchowk District And Nepalese Employed Abroad From Mangsir 10
Mon, Nov 16, 2026 9:08 AM on IPO/FPO News, Highlight News,
Kantipur Pharmaceuticals Lab Limited has published an offer letter to issue an Initial Public Offering (IPO) to the project-affected locals of Kavrepalanchowk District and Nepalese citizens working abroad.
The IPO issue for the locals of Kavrepalanchowk District will open from 10th Mangsir to 24th Mangsir, 2083, with a possible extension till Poush 13, 2083, if not fully subscribed by the early closing date, while for Nepalese citizens working abroad, the issue will open from 10th Mangsir to 15th Mangsir, 2083, and may be extended till 24th Mangsir if undersubscribed.
The issued capital of the company is Rs. 80 Crores. Of this, 21.25%, i.e., 17,00,000 unit shares, will be issued to the public. Out of the total issued capital, 10%, amounting to 8,00,000 unit shares worth Rs. 8.00 crore, will be allocated to project-affected locals in Kavrepalanchowk District. The remaining 11.25% of the issued capital, i.e., 9,00,000 unit shares, will be offered to the general public.
Of this general public issue, 10% of 9,00,000, a total of 90,000 unit shares, have been set aside for Nepalese citizens working abroad, and the issue for this category will open on the date mentioned above.
For the project-affected locals, the minimum application quantity to be applied is 10 units, while the maximum quantity is 10,000 units. For Nepalese citizens working abroad, the minimum application quantity is 10 units, and the maximum is 7,000 units.
Muktinath Capital Limited has been appointed the issue manager for the public offering.
CARE Ratings Nepal Limited (CRNL) has reaffirmed the ‘CARE-NP BB+ (Is)’ issuer rating assigned to Kantipur Pharmaceuticals Lab Limited (KPL), indicating a moderate level of risk of default in the timely servicing of its financial obligations in Nepal.
Kantipur Pharmaceuticals Lab Limited (KPL) was converted from a private limited company into a public limited company on July 9, 2024. The company is engaged in the manufacturing of veterinary pharmaceutical products, with its manufacturing plant located in Panchkhal-7, Kavre, Nepal. KPL offers a diverse range of products, including allopathic veterinary medicines, animal nutrition products, feed additives, phyto-feed additives, and other animal health solutions. The company aims to support animal health by providing reliable products for cattle and poultry, catering to the growing requirements of Nepal’s veterinary industry.
